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Purpose: To assess prostate-speciﬁc antigen (PSA) kinetics and report on the oncologic outcomes for
patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT) using
CyberKnife.
Methods: We extracted the list and data of 39 patients with clinically localized prostate cancer who had
undergone primary SBRT using CyberKnife between January 2008 and December 2012 from the Smart
Prostate Cancer database system of Seoul St. Mary's Hospital. Changes in PSA over time, PSA velocity, and
PSA nadir were evaluated from the completion of SBRT using CyberKnife. Biochemical recurrence (BCR)-
free survival after primary SBRT using CyberKnife was determined using KaplaneMeier analysis.
Results: The rate of PSA decrease was maximal in the ﬁrst month (median 3.34 ng/mL/mo), which then
fell gradually with median values of 1.51, 0.32, 0.28, 0.20, and 0.03 ng/mL/mo for durations of 3,
6, 9, 12, and 24 months after SBRT using CyberKnife, respectively. The median PSA nadir was 0.31 ng/mL
after a median 23 months. KaplaneMeier analysis calculates an actuarial 5-year BCR-free survival after
SBRT using CyberKnife as 80.8%.
Conclusions: PSA decline occurred rapidly in the ﬁrst month, and then the rate of PSA decline fell off
steadily over time throughout 2 years after treatment. Also, SBRT using CyberKnife leads to long-term
favorable BCR-free survival in localized prostate cancer.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the most common cancer of all newly diag-
nosed male cancers, and the second leading cause of cancer death
in the United States.1 The American Cancer Society estimates that
prostate cancer will be expected to account for 28% of incidentmale
cancer cases in 2013. The majority of prostate cancer is localized,
and various curative treatment options have aimed to improve the
oncologic and functional outcomes of these patients. Radical
prostatectomy and external beam radiation therapy (EBRT) is the
conventional treatment option for localized prostate cancer.ool of Medicine, The Catholic
anpo-dong, Seocho-gu, Seoul
ier B.V. on behalf of Prostate InteHowever, these treatment modalities are limited by the need for
anesthesia, several functional impairments, and long treatment
duration.
Stereotactic body radiation therapy (SBRT) via CyberKnife
(Accuray, Sunnyvale, CA, USA) uses real-time image guidance to
account for intrafraction prostatic motion.2 It can facilitate delivery
of an optimal therapeutic dose to the prostate with a rapid dose
falloff near the targeted lesion, resulting in potentially better local
control. Recent studies have reported that SBRT using CyberKnife in
patients with low or intermediate risk has achieved excellent
biochemical recurrence (BCR) free survival.3e5
Prostate-speciﬁc antigen (PSA) is a well-established biomarker
for prostate cancer which can be used to monitor response to
treatment. Changes in PSA and its derivatives after radical prosta-
tectomy or EBRT have been extensively researched. However, PSA
kinetics in response to SBRT using CyberKnife remains poorly un-
derstood. Thus far, only a few studies from western countriesrnational. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Baseline demographics of the patients.
Variables
Age (y)a 70.8, 72.0 (68.0e75.0)
BMI (kg/m2a)* 23.5, 24.4 (21.7e26.0)






Pretreatment PSA (ng/mL)a 9.2, 8.4 (6.2e11.1)
Prostate volume (cm3)a 34.6, 35.0 (20.5e45.7)
PSA density (ng/mL/g)a 0.36, 0.22 (0.14e0.53)




No. total biopsy coresa 10.3, 10.0 (10.0e12.0)
No. positive coresa 2.6, 2.0 (2.0e3.0)










BMI, body mass index; NCCN, National Comprehensive Cancer Network.
a Values are expressed as mean, median (interquartile range).
Fig. 1. Prostate-speciﬁc antigen changes after stereotactic body radiation therapy using
CyberKnife.
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Knife.6,7 Due to racial differences in longitudinal changes in serum
PSA levels,8 it is necessary to elucidate changes in PSA after SBRT
using CyberKnife in Asian populations. The purpose of the current
study is to assess PSA kinetics and report oncologic outcomes for
patients with localized prostate cancer treated with SBRT using
CyberKnife.
2. Methods
The protocol of this study was approved by the Institutional
Review Board at the Catholic University of Korea, Seoul St. Mary's
Hospital. We extracted the list and data of 46 patients with
clinically localized prostate cancer who had undergone primary
SBRT using CyberKnife between January 2008 and December
2012 from the Smart Prostate Cancer database system of Seoul St.
Mary's Hospital.9 Treatment was delivered using CyberKnife with
doses of 35 Gy or 36.25 Gy in ﬁve fractions.10 Included patients
had at least 1 year of follow up, and four serial PSA assays. To
insure a uniform population in which to evaluate PSA outcomes,
patients were excluded if they received neoadjuvant or adjuvant
androgen deprivation therapy (ADT, n ¼ 4), or used 5-a reductase
inhibitors (n ¼ 3). Thus, a total of 39 patients were included in
this study.
The primary endpoint was to assess PSA changes in response to
SBRT using CyberKnife. The secondary endpoint was to determine
the potential long-term clinical outcomes after primary SBRT using
CyberKnife. Clinical outcome measures included age, body mass
index (BMI), Karnofsky performance status scale, serum PSA level,
biopsy Gleason score, clinical stage, and BCR. To summarize PSA
measurements during the follow-up period, PSA velocity was
estimated as the rate of change of PSA over time (ng/mL/y). PSA
values taken after the start of ADT were excluded. PSA bounce was
deﬁned as an absolute increase of 0.2 ng/mL from the previous PSA
level, followed by a subsequent decrease.11 Biochemical recurrence
was deﬁned as an increase of at least 2 ng/mL from the nadir PSA
according to the Phoenix deﬁnition.12 Finally, patients were
stratiﬁed into three risk groups (low, intermediate, and high)
based on the National Comprehensive Cancer Network (NCCN) risk
group.13
Statistical analysis was performed using the IBM SPSS software,
version 19.0 (SPSS, Inc., IBM, Chicago, IL, USA). Continuous variables
are presented as mean; median (interquartile range [IQR]), and
categorical variables are presented as proportions. BCR-free sur-
vival was estimated using the KaplaneMeier method.
3. Results
3.1. Baseline demographics
The baseline characteristics of the 39 patients are presented in
Table 1. The mean age was 70.8 (IQR, 68e75) years, and the mean
body mass index was 23.5 (IQR, 21.7e25.9) kg/m2. The mean serum
PSA level was 9.2 (IQR, 6.2e11.1) ng/mL, and NCCN risk groups were
distributed as follows: low, 11 (28.2%); intermediate, 25 (64.1%);
and high, 3 (7.7%).
3.2. PSA changes after SBRT using CyberKnife
The median follow-up duration was 53.0 (IQR, 26.0e68.0)
months. Fig. 1 shows PSA changes declining over time, with the
different PSA velocities for each time intervals since SBRT using
CyberKnife. The rate of PSA decrease was maximal in the ﬁrst
month (median 3.34 ng/mL/mo), then gradually falling off with
median values of 1.51, 0.32, 0.28, 0.20, and 0.03 ng/mL/mofor duration of 3, 6, 9, 12, and 24 months after SBRT using Cyber-
Knife, respectively. The median PSA nadir was 0.31 (IQR, 0.12e0.67)
ng/mL after a median 23 months.
Fourteen patients (35.9%) experienced a PSA bounce during the
follow-up period. The median time to PSA bounce was 11 (IQR,
6.0e18.5) months; 92.8% (13/14) of PSA bounces were seen within
24 months after SBRT using Cyberknife. The median PSA level
before the bouncewas 1.07 (IQR, 0.34e2.54) ng/mL, and themedian
height of PSA bounce was 0.40 (IQR, 0.2e1.20) ng/mL. Patients with
PSA bounces had lower pretreatment PSA levels (10.8 vs. 7.5 ng/mL,
P ¼ 0.039), and only pretreatment PSA level was associated with
increased risk of PSA bounce on multivariated logistic regression
analysis (odds ratio ¼ 0.786, 95% conﬁdence
interval ¼ 0.614e0.987, P ¼ 0.043).
Fig. 2. Biochemical recurrence rate after stereotactic body radiation therapy using
CyberKnife in the overall patient population.
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Four BCRs (12.8%) were observed over a median follow-up
duration of 42.0 (IQR 18.0e64.0) months. In univariate
KaplaneMeier analysis, the actuarial 5-year BCR-free survival was
80.8% (Fig. 2). Two patients in the intermediate-risk group and two
in the high-risk group experienced BCRs. Five-year BCR-free sur-
vival was 100% for low-risk, 83.9% for intermediate-risk, and 33.3%
for high-risk patients (Fig. 3A, P¼ 0.033). When categorized by PSA
bounce, BCR was not observed in patients with PSA bounce,
whereas four BCRs were observed in patients without PSA bounce.
Although not reaching statistical signiﬁcance, the 5-year BCR-free
survival was 100% for patients with PSA bounce versus 68.7% for
the patients without PSA bounce (Fig. 3B, P ¼ 0.100).Fig. 3. Biochemical recurrence rate after stereotactic body radiation therapy us4. Discussion
In the current study, we described the changes in the serum PSA
levels in patients with localized prostate cancer treated with SBRT
using CyberKnife. The majority of PSA decline occurred in the 1st
month, following which the rate of PSA decline fell off steadily over
time for 2 years after treatment. Several reports have shown PSA
kinetics after SBRT using CyberKnife.14e16 Bolzicco et al15 demon-
strated that the patients with SBRT monotherapy had PSA nadirs of
0.93 ng/mL, 0.87 ng/mL, and 0.62 ng/mL at 1, 2, and 3 years.15 Katz
et al14 reported that PSA decline after SBRT gradually fell to an
overall median of 0.20 ng/mL at 3 years17 and 0.12 ng/mL at 5
years.14 Anwar et al6 compared the PSA kinetics between conven-
tionally fractionated external beam radiotherapy and SBRT in
localized prostate cancer, and reported that the median PSA nadirs
and slopes for SBRT were 0.70, 0.40, 0.24 ng/mL
and 0.09, 0.06, 0.05 ng/mL/mo at 1, 2, and 3 years, respec-
tively.6 In our study, PSA velocity after SBRT using CyberKnife
was 3.34, 1.51, 0.32, 0.28, 0.20, and 0.03 ng/mL/mo at 1, 3,
6, 9, 12, and 24 months. In Korean men, PSA levels after SBRT tends
to be decreasing more rapidly and lower compared to Western
men. This may be due to underlying biologic differences between
Asian and Western men, but any racial differences in PSA kinetics
after SBRT or other radiation therapies need further elucidation in
future studies.
In this study, PSA bounce was seen in 35.9% of patients after
SBRT using CyberKnife. Incidence of PSA bounce after SBRT using
CyberKnife has been reported diversely from 17% to 31% according
to the varying deﬁnitions.14,16,18 The predictors of PSA bounce in
patients undergoing SBRT has been studied, and McBride et al18
found that patients with PSA bounce were younger than those
without PSA bounce. Vu et al19 analyzed the clinical and pathologic
predictors of PSA bounce in patients after SBRT, and reported that
younger age was the predictive factor for PSA bounce (odds
ratio ¼ 0.937, 95% conﬁdence interval ¼ 0.892e0.984, P ¼ 0.009)
(19). However, age was not associated with increased risk of PSA
bounce and only pretreatment PSA level was associated with
increased risk of PSA bounce in our study. Our study suggests that
further studies are necessary to elucidate the predictive factors for
PSA bounce after SBRT.ing CyberKnife according to the (A) NCCN risk group and (B) PSA bounce.
Y.H. Park et al. / Prostate International 3 (2015) 6e9 9We also found that SBRT using CyberKnife leads to long-term
favorable BCR-free survival in localized prostate cancer. Radiobio-
logically, slowly growing prostate cancer cells are thought to have a
low a/b ratio consistently less than 3.6,20,21 This low a/b ratio sug-
gests that prostate cancer cells are highly sensitive to dose per
fraction, which means that a hypofractionated radiation therapy
with a large radiation dose delivered in a smaller number of frac-
tions may be advantageous. Several studies suggest that SBRT may
provide similar excellent biochemical control as other radiation
modalities. According to the risk group, 4- or 5-year BCR-free sur-
vival was known to be 93e97% for low-risk,3,14,22,23 86.2e92% for
intermediate-risk,14,23,24 and 77.7e80% for high-risk patients.14,23
These results are consistent with ours; however, BCR-free survival
in high-risk patients was poor in our study. It may result from the
delayed start of ADT. Patients with high-risk prostate cancer may be
considered for long-term neoadjuvant/concomitant/adjuvant
ADT.13 However, we delayed ADTafter BCR because of the history of
ischemic heart disease of these two patients. They commenced ADT
immediately after BCR, and were still alive at follow-up duration of
47 and 64 months, respectively.
Our study has several important limitations. First, our study is
limited by its retrospective nature, the small number of patients,
and relatively short follow-up duration. Therewere no protocols for
the clinical decision-making process and follow up. Furthermore,
we did not perform assessments of the toxicity and quality of life
among patients who received SBRT using CyberKnife. Therefore,
validated questionnaires still need to be used to deﬁne the ad-
vantages and disadvantages of this treatment modality. Addition-
ally, in order to accurately estimate the PSA kinetics, patients who
received neoadjuvant or adjuvant ADT were excluded. Nonetheless,
we believe that these results are still notable because few studies
have been done to assess PSA kinetics after SBRT using CyberKnife
in Asian patients with localized prostate cancer.5. Conclusion
Themajority of PSA decline occurred in the 1st month, and then,
the rate of PSA decline fell off steadily over time with a continuing
drop at 2 years after treatment. PSA bounce was seen in a signiﬁ-
cant proportion of patients after SBRT using CyberKnife. We also
conﬁrmed that SBRT using CyberKnife leads to long-term favorable
BCR-free survival in localized prostate cancer.Conﬂict of interest
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